Bal Pharma launches Favipiravir tablets in India

Favipiravir is an emerging antiviral drug used for patients with mild to moderate C-19 infection.

53
Medicine Tablet
Picture: Pixabay

Bal Pharma announced the launch of Favipiravir formulation in the Indian market, under the brand name BALflu.

Favipiravir is an emerging antiviral drug used for patients with mild to moderate C-19 infection. This formulation is available in tablets form with 400 mg strength. Favipiravir inhibits and terminates viral protein synthesis and induces lethal metagenesis of the influenza virus.


Also read more articles on Favipiravir, click here


BALflu is a broad spectrum formulation also used in the treatment of 53 types of Influenza virus including seasonal strains such as Ebola virus, arenavirus, bunyavirus, filovirus, West Nile virus, foot and mouth disease virus and Lassa virus.

Medicine Tablets
Picture: Pixabay

BALflu (favipiravir) is approved by the Drug Controller General of India (DCGI) for emergency use for the treatment of C-19 with a recommended dosage of 1800 mg on the first day followed by 800 mg from day 2 to 14.

Shailesh Siroya, MD, Bal Pharma said that the BALflu has the efficacy to clear the virus faster by 28.7 per cent and is marketed at a price of Rs 85 per tablet.

BALflu is made available across all the major markets in India as a prescription drug.


Other approvals:

Glenmark gets USFDA nod for Icatibant injection single-dose prefilled syringe

NATCO Pharma gets USFDA nod for Everolimus tablets

Natco Pharma gets USFDA nod for Lenalidomide capsules

Unichem Labs gets USFDA approval for Amitriptyline HCL Tablets

Alembic gets USFDA Final nod for Lurasidone HCL Tablets

Alembic gets USFDA nod for depression treatment drug


Also read:

NABL mandates QR code on test reports of Laboratories

Govt opens on-site registration for 18-44 years age for vaccination

Zydus Cadila launches drug for Breast cancer treatment

Glenmark gets USFDA nod for Icatibant injection single-dose prefilled syringe

NATCO Pharma gets USFDA nod for Everolimus tablets

Bharat Parenterals gets DCGI nod for Favipiravir oral suspension

Subscribe for daily free updates on Telegram

Follow us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Enter your email address:

Delivered by FeedBurner